http://orcid.org/0000-0001-9108-6660
About the Authors
- Alyssa Bilinski
-
* E-mail: abilinski@g.harvard.edu
Affiliation Interfaculty Initiative in Health Policy, Harvard University, Cambridge, Massachusetts, United States of America
- Peter Neumann
-
Affiliation Center for Evaluation and Risk in Health, Tufts Medical Center, Boston, Massachusetts, United States of America
- Joshua Cohen
-
Affiliation Center for Evaluation and Risk in Health, Tufts Medical Center, Boston, Massachusetts, United States of America
- Teja Thorat
-
Affiliation Center for Evaluation and Risk in Health, Tufts Medical Center, Boston, Massachusetts, United States of America
- Katherine McDaniel
-
Affiliation School of Social and Political Science, University of Edinburgh, Edinburgh, Scotland, United Kingdom
- Joshua A. Salomon
-
Affiliations Center for Health Policy and the Center for Primary Care and Outcomes Research, Stanford University, Stanford, California, United States of America, Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America
Competing Interests
I have read the journal's policy and have the following conflicts: PN has served on health economic advisory boards for the Congressional Budget Office, Merck, Bayer, Pacira, Novo Nordisk, Janssen, and AstraZeneca and consulted for Vertex and Precision Health Economics. JC has consulted for Axovant, Merck, Partnership for Health Analytic Research, Precision Health Economics, and Veritech Corporation. The Center for the Evaluation of Value and Risk receives funding from a variety of government, private foundation, and pharmaceutical industry sources. AB, JAS, KM, and TT report no conflicts of interest.